TGR-1202 and carfilzomib synergistically disrupt the 4E-BP1–eIF4F–c-Myc axis. Cell lines, including (A) LY10, (B) LY7, (C) PF382, and (D) H929, and primary cancer cells from patients with (E) SLL and (F) CLL were treated by TG, Ide, Cfz, Bz, and their combinations as indicated for 24 hours. In the H929 cell line, TC-1 and TC-2 indicate TGR at 5 μM in combination with carfilzomib at 6 and 7 nM, respectively. Cell were harvested and processed for western blot analysis using the antibodies against 4E-BP1, c-Myc, β-actin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH).